Mia's Feed
Medical News & Research

Innovative Diagnostic Tool Accelerates Identification of Rare Genetic Diseases in Children

Innovative Diagnostic Tool Accelerates Identification of Rare Genetic Diseases in Children

Share this article

A new proteomics-based diagnostic test is revolutionizing the detection of rare genetic diseases in children, reducing diagnosis time from weeks to days and improving outcomes for affected families.

2 min read

The process of diagnosing rare genetic diseases in children has historically been lengthy and challenging, often involving numerous tests, hospital visits, and specialist consultations. Despite the definition of "rare" implying infrequent occurrence, these conditions collectively impact approximately 2 million Australians, equating to around 8% of the population. Advances in genomics have improved diagnostic rates, with about half of affected families receiving answers within months. However, many still face a protracted "diagnostic odyssey," undergoing invasive and time-consuming tests that may not conclusively identify the disease.

To address this, researchers at the University of Melbourne have developed a groundbreaking diagnostic test that works in tandem with genome sequencing data. Published in Genome Medicine, this proteomics-based test enables rapid interpretation of genetic variants by analyzing proteins in the blood, offering results in as little as three days—an improvement over the weeks or months traditional methods require.

This innovative test is not limited to a specific disorder but covers thousands of known disease-causing mutations, providing a scalable and cost-effective alternative to multiple functional tests. It is particularly effective in neonatal intensive care units, facilitating early diagnosis in critically ill infants.

A poignant example of its impact is the case of a family who lost their first child due to mitochondrial disease. Utilizing stored samples, clinicians confirmed the genetic diagnosis swiftly, enabling prenatal testing in subsequent pregnancies. This allowed the birth of a healthy child and exemplifies how early, accurate diagnosis can prevent family grief and enable informed reproductive choices.

Looking ahead, the team is recruiting additional patients to validate the test's utility across various genetic conditions. The ultimate goal is to integrate this technology into national healthcare services, making quick and affordable diagnosis accessible to as many families as possible.

This development marks a significant step forward in reducing the diagnostic burden and improving outcomes for children with rare genetic conditions.

Source: https://medicalxpress.com/news/2025-05-diagnosis-journey-children-born-rare.html

Stay Updated with Mia's Feed

Get the latest health & wellness insights delivered straight to your inbox.

How often would you like updates?

We respect your privacy. Unsubscribe at any time.

Related Articles

New Long Noncoding RNA Identified as Potential Target for Prostate Cancer Therapy

A new study identifies a specific long noncoding RNA, PRCAT71, as a potential biomarker and therapeutic target for prostate cancer, revealing new pathways for treatment.

Innovative Oral Swab Test Guides Effective Hormone Therapy for IVF Success

A quick and non-invasive oral swab test can now predict the most effective hormone therapy for women undergoing IVF, increasing success rates and reducing side effects. Developed by Lund University, this innovative test personalizes fertility treatment based on genetic markers, promising to improve reproductive outcomes.

Liquid Biopsy-Driven Treatment Switch Enhances Outcomes in Breast Cancer Recurrence

A groundbreaking clinical trial shows that early detection of resistance mutations via liquid biopsy and switching to experimental drugs can significantly improve outcomes for advanced breast cancer patients.